Journal Logo

Research Article: Study Protocol Systematic Review

Impact of the numbers of injections of platelet rich plasma on the clinical outcomes in patients with knee osteoarthritis

A protocol for an updated network meta-analysis

Wang, Pan B.S.Meda; Li, Kai B.S.Meda; Jiang, Zuxin M.Meda; Qiu, Beiming B.S.Meda; Nie, Cheng B.S.Meda; Luo, Hongsheng B.S.Meda; Li, Zhengjiang M.Medb,∗

Author Information
doi: 10.1097/MD.0000000000024250
  • Open

Abstract

1 Introduction

Knee osteoarthritis (KOA) is a degenerative disease,[1] which was associated with cartilage degeneration and exfoliation, and subchondral bone hyperplasia, knee pain, joint instability and functional limitations.[2–4] As a common disabling disease, KOA has been estimated to affect more than 250 million people worldwide.[5] It is noted that articular cartilage regeneration is very difficult; once damaged, it is difficult to repair.[6] And thus, KOA can seriously negatively impact the patients quality of life.[7] Although knee replacement surgery provides an effective solution for severe knee KOA,[8] the Osteoarthritis Society International (OARSI) recommends conservative treatment rather than surgery as the first-line management solution for KOA, which emphasizes the importance of conservative treatment in the treatment of KOA.[9]

As one of the conservative treatments, injectable medications such as hyaluronic acid (HA), steroids, nonsteroidal antiinflammatory drugs, and platelet-rich plasma (PRP) have been proved having ability of promoting the regeneration in tissue and alleviation of symptoms.[10–12] Among injectable options for symptom relief and functional improvement in patients with knee OA, PRP has increased in popularity in recent years.[13] Several systematic reviews and meta-analyses have further determined the potential of PRP in treating KOA.[1,2,14–22]

After demonstrating the efficacy of PRP for the treatment of KOA, researchers and practitioners changed attention to further explore the optimal numbers of PRP injection. To date, several randomized controlled trials[23–29] focused on this topic have been reported, and a recent meta-analysis[30] has also compared clinical effectiveness of single versus multiple injections of platelet-rich plasma in the treatment of knee osteoarthritis and suggested that a single injection was as effective as multiple PRP injections in pain improvement; however, multiple injections seemed more effective in joint functionality than a single injection at 6 months. Moreover, a recent network meta-analysis also investigated the comparative efficacy of single between multiple injections for the treatment of KOA, and found no significant difference of these two regimes for pain relief and improvement of joint function.[1]

Unfortunately, 2 previous meta-analyses all missed some eligible studies,[23,28] which obviously impaired the robustness of pooled results. Moreover, these 2 meta-analyses[1,30] only investigated the comparative efficacy of single and multiple injections, multiple injections including double and triple options were not investigated separately. Thus, previous meta-analyses have limited reference value for making decision in clinical practice. Considering these issues, we designed this updated study with traditional meta-analysis and network meta-analysis techniques to further investigate the role of multiple injections and comparative efficacy of double and triple injections among KOA patients.

2 Methods

We registered this protocol on the International Plateform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) website and received a register number of INPLASY2020110043 (https://inplasy.com/inplasy-2020-11-0043/), and thus our protocol has been funded through a protocol registry. We will use the recommendations in the Cochrane handbook[31] as the methodological framework to instruct performing this updated network meta-analysis. After finishing all statistical analyses, we will also use the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement to guide reporting all results.[32] We will perform all analyses based on previous studies, and thus no ethical approval from the institutional review board and patients informed consent will be required.

2.1 Identification of studies

Because previous topic-related meta-analysis searched all potential citations published between 1970 to July 2019,[30] therefore we will perform an additional search to capture any potential records reported between August 2019 and October 2020. The additional search will be conducted by 2 independent reviewers in PubMed, Embase, and China National Knowledgement Infrastructure (CNKI). We will use the combination of text words and MeSH terms to construct a search strategy and amend to be applicable to individual database according to the unique requirements of each database. The search strings of PubMed and Embase were documented in Table 1. We will also manually check the reference lists of all eligible studies and meta-analyses tin order to include any potential studies. The process of searching and selecting potentially eligible studies will be delineated in Figure 1. Any disagreements about identification of studies will be resolved through consulting a third senior reviewer.

Table 1 - Search strategy.
1. Search strategy of PubMed
Search number Search terms
10 ((((“Osteoarthritis, Knee” [Mesh]) OR ((((Knee Osteoarthritides [Title/Abstract]) OR (Knee Osteoarthritis [Title/Abstract])) OR (Osteoarthritis of Knee [Title/Abstract])) OR (Osteoarthritis of the Knee [Title/Abstract]))) AND ((“Platelet-Rich Plasma”[Mesh]) OR ((Platelet-Rich Plasma [Title/Abstract]) OR (Platelet Rich Plasma [Title/Abstract])))) AND (random)) AND ((“2019/08/01” [Date - Entry]: “3000” [Date - Entry]))
9 (“2019/08/01” [Date - Entry]: “3000” [Date - Entry])
8 (((“Osteoarthritis, Knee” [Mesh]) OR ((((Knee Osteoarthritides [Title/Abstract]) OR (Knee Osteoarthritis [Title/Abstract])) OR (Osteoarthritis of Knee [Title/Abstract])) OR (Osteoarthritis of the Knee [Title/Abstract]))) AND ((“Platelet-Rich Plasma” [Mesh]) OR ((Platelet-Rich Plasma [Title/Abstract]) OR (Platelet Rich Plasma [Title/Abstract])))) AND (random)
7 random
6 (“Platelet-Rich Plasma” [Mesh]) OR ((Platelet-Rich Plasma [Title/Abstract]) OR (Platelet Rich Plasma [Title/Abstract]))
5 (Platelet-Rich Plasma [Title/Abstract]) OR (Platelet Rich Plasma [Title/Abstract])
4 “Platelet-Rich Plasma”[Mesh]
3 (“Osteoarthritis, Knee” [Mesh]) OR ((((Knee Osteoarthritides [Title/Abstract]) OR (Knee Osteoarthritis [Title/Abstract])) OR (Osteoarthritis of Knee [Title/Abstract])) OR (Osteoarthritis of the Knee [Title/Abstract]))
2 (((Knee Osteoarthritides [Title/Abstract]) OR (Knee Osteoarthritis [Title/Abstract])) OR (Osteoarthritis of Knee [Title/Abstract])) OR (Osteoarthritis of the Knee [Title/Abstract])
1 “Osteoarthritis, Knee” [Mesh]
2. Search strategy of Embase
Search number Search terms
#9 #8 AND (2019:py OR 2020:py)
#8 #3 AND #6 AND #7
#7 random
#6 #4 OR #5
#5 “thrombocyte rich plasma”/exp OR “platelet-rich plasma cell”/exp
#4 “platelet rich plasma”: ti,ab,kw OR “thrombocyte rich plasma”: ti,ab,kw OR “platelet-rich plasma”: ti,ab,kw
#3 #1 OR #2
#2 “knee osteoarthritis”/exp
#1 “knee osteoarthritides”: ti,ab,kw OR “knee osteoarthritis”: ti,ab,kw OR “osteoarthritis of knee”: ti,ab,kw OR “osteoarthritis of the knee”: ti,ab,kw

Figure 1
Figure 1:
Flow diagram of study retrieval and selection. CNKI, China National Knowledgement Infrastructure. Additional records will be identified from previous meta-analysis.

2.2 Selection criteria

We will develop the inclusion and exclusion criteria according to the previous meta-analysis.[30] Generally speaking, patients who were clinically and radiographically diagnosed with KOA defined by any recognized diagnosis criteria, and with a minimum follow-up of 3 months were deemed to be eligible. We will only consider randomized controlled trials (RCTs) investigating the effect of the number of PRP injections regardless of category on clinical outcomes including pain (measured with visual analog scale [VAS] or visual numerical scale [VNS]) and joint function (measured with Western Ontario and McMaster Universities Arthritis Index [WOMAC], International Knee Documentation Committee [IKDC] subjective knee evaluation form, or Lequesne index [LI]) among KOA patients. Only research reported in English or Chinese language will be considered to be eligible.

We will exclud review, case report, case series, and observational studies including quasi-experimental research, cohort study, case-control study, and cross-sectional study. We will also exclud studies without sufficient data if additional information cannot be obtained since contacted leading author. About duplicate records, we will exclude 1 which was presented previously or have insufficient information. Any disagreements about the selection of studies will be solved by consulting a third senior reviewer.

2.3 Data extraction

Two independent reviewers will utilize the data extraction sheet to perform data extraction. According to the purpose of the present meta-analysis, we will extract the following data: characteristics of studies including the first author name, publication year, and country, information of patients including sample size, age, gender, and body mass index (BMI), details of interventions including regimes of all arms, duration of treatment, measurement tool for outcome, and outcomes of interesting, as well as details of risk of bias of each study. The basic characteristics of all eligible studies will be summarized in Table 2. The corresponding author will be contacted when sufficient information can be not available. Any disagreements about data extraction will be resolved by consulting a third senior investigator.

Table 2 - Basic characteristics of all eligible studies.
Details of treatments
Study Country Sample size Age, yrs BMI (kg/m2) Single Double Triple Treatment Duration, mo Outcomes
Study 1
Study 2
Study 3
Study 4
Study 5
Study 6
Study 7
BMI = body mass index, mo = month, yrs = years.

2.4 Assessment of risk of bias

We will grade the quality of each eligible study according to the assessment result of the risk of bias, which will be appraised with the Cochrane risk of bias assessment tool.[33] Risk of bias will be examined according to the following 6 domains[34]: randomization, allocation, blind, incomplete data, selectively reported and other bias sources. A study will be allocated to have a label of “low”, “unclear”, or “high” risk of bias according to the match level between actual information and criteria. Any divergency at risk of bias will be resolved by a third senior investigator. Eventually, we will obtain the overall quality of an individual study (low, moderate or high quality) according to the result of labelling of the risk of bias.

2.5 Statistical analysis

In our meta-analysis, all outcomes are measured as a numerical scale with various measurement tools. Therefore, we will express it as standard mean difference (SMD) with 95% confidence interval (CI). We will firstly qualitatively inspect the heterogeneity across studies with the Chinese square test (Q statistic), and then quantitatively estimate the heterogeneity using I2 statistic.[35] All studies will be thought to be homogenesis when P > .10 and I2 < 50%. Otherwise, studies will be considered heterogeneous when P < .1 and I2 ≥ 50. For studies reporting the standard error of the mean (se), we will calculate the standard deviation (sd) according to the method recommended by Cochrane handbook.[34] When not able to obtain the SD of a record after trying to contact the study authors, we will use the range-rule-of-thumb method to estimate the missing SD.[36] Moreover, we will use net changes in measurements, which will be estimated using the method recommended by Cochrane handbook[34] to estimate the efficacy of all treatments. A P value <.05 will be defined as the threshold for statistical significance. We will perform traditional direct meta-analysis based on the random effects model depending on the Review Manager (RevMan) version 5.3 (Cochrane Collaboration, Copenhagen, Denmark). We will drew funnel plot to inspect the possibility of presence of publication bias when the accumulated number of eligible studies for individual outcome was greater than 10.[37]

After investigating direct comparisons of single vs multiple injections, single vs double injections, and single vs triple injections, we will also perform network meta-analysis to investigate the comparative efficacy of double and triple injections with Open BUGS software version 3.2.3 (MRC Biostatistics Unit, Cambridge, UK) following methods described by Lu and Ades.[38,39] We will use the initial value which is automatically generated from software to fit the model.[40] To gain convergence, we will perform each Markov chain Monte Carlo chain with 50,000 iterations and 20,000 burn-in. The summary treatment effect estimates will be described as SMD, with 95% credible interval (CrI), for treatment comparisons.

3 Discussion

3.1 Rational basis of designing this updated network meta-analysis

Knee joint osteoarthritis (KOA) is the main cause of joint degeneration in older individuals. The disease process is characterized by articular cartilage degeneration and whole joint disease.[3,4] These lesions result in joint dysfunction and pain, which can seriously negatively impact the patients quality of life. Intra-articular platelet-rich plasma (PRP) have been extensively utilized to treat KOA, and several meta-analyses have been demonstrated the efficacy of PRP for improving clinical outcomes among KOA patients compared to other intra-articular treatments.[20,41–43] Meanwhile, 2 meta-analyses[1,30] also performed in order to know the appropriate number of injections required to achieve clinical improvement, however conflicting findings were obtained. Moreover, recent studies[23,28] were not included in previous meta-analyses and comparative efficacy of separate multiple injections was not investigated. Therefore, we designed the present meta-analysis to comprehensively address these problems.

3.2 Potential mechanisms of PRP for KOA

PRP is a novel growth factor produced via centrifuging autologous whole-blood and isolation of high platelet count plasma.[44,45] Platelets have promising regenerative capacity because their a-granules contain many growth factors such as transforming growth factor-beta, platelet-derived growth factor, epidermal growth factor, vascular endothelial growth factor, fibroblast growth factor, and insulin-like growth factor.[46,47] Moreover, many cytokines (such as unclear factor-kappa B, interleukin-1, and nitric oxide) contained in PRP have also the ability of inhibiting inflammatory effects on chondrocytes.[48,49] Up to now, PRP has been extensively utilized to treat the conditions occurred in bone, cartilage, and soft tissue.[50] Considering the value in promoting regeneration, PRP has also now increasingly been extended to utilize in orthopedics and sport medicine.[51] Certainly, several studies have further demonstrated the possible chondroprotective activity of PRP.[17]

3.3 Limitations of the present meta-analysis

Regardless of the fact that this current updated network meta-analysis have several advantages compared to previous published meta-analyses, some limitations existed in this study should be cautiously explained. Firstly, we will only search PubMed, Embase and CKNI to identify additional studies, potentially eligible studies indexed in other databases such as SCOPUS may be missed. Second, a published care report[52] have suggested that multiple injections may have positive effective for advanced grades of KOA, however we will not design subgroup analysis to explore the impact of severity of KOA on treatment effects due to limited data after initially screening literatures.

3.4 Study status

This updated network meta-analysis has been registered on the INPLASY on November 10, 2020 (Registration Number: INPLASY2020110043). Under the guidance of the PRISMA, our current study has begun, and the search strings have been constructed. We planned to complete data extraction on March 31, 2020 and the report the overall review on December 30, 2020.

3.5 Ethics and dissemination

Ethics approval and patients informed consent will not be required in the current updated network meta-analysis because all statistical analyses will be performed based on published data. After completing this updated network meta-analysis, we will communicate our findings through submiting it to peer-reviewed journal and academic conferences.

Acknowledgments

We would like to deeply appreciate the International Plateform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) platform for acceptance of our application of registering this protocol.

Author contributions

PW, KL, and ZJL conceived and designed this protocol. ZXJ, BMQ, CN, and HSL reviewed scoping searches and contributed to the methodological development of the protocol. PW and KL drafted the manuscript and other authors critically made a revision. All authors reviewed and approved the final version for publication. PW is the review guarantor.

Conceptualization: Pan Wang, Kai Li, Zhengjiang Li.

Data curation: Beiming Qiu, Cheng Nie.

Formal analysis: Pan Wang, Kai Li, Zhengjiang Li.

Investigation: Zuxin Jiang, Beiming Qiu, Hongsheng Luo.

Methodology: Kai Li.

Resources: Zuxin Jiang, Beiming Qiu, Cheng Nie, Hongsheng Luo.

Software: Pan Wang, Cheng Nie, Hongsheng Luo.

Supervision: Zhengjiang Li.

Writing – original draft: Pan Wang, Kai Li.

Writing – review & editing: Zhengjiang Li.

References

[1]. Han S-B, Seo I-W, Shin Y-S. Intra-Articular Injections of Hyaluronic Acid or Steroids Associated With Better Outcomes Than Platelet-Rich Plasma, Adipose Mesenchymal Stromal Cells, or Placebo in Knee Osteoarthritis: A Network Meta-Analysis. Arthroscopy 2020;37:292–306.
[2]. Pereira D, Peleteiro B, Araújo J, et al. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage 2011;19:1270–85.
[3]. Kurien T, Arendt-Nielsen L, Petersen KK, et al. Preoperative neuropathic pain-like symptoms and central pain mechanisms in knee osteoarthritis predicts poor outcome 6 months after total knee replacement surgery. J Pain 2018;19:1329–41.
[4]. Rausch Osthoff AK, Niedermann K, Braun J, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheumatic Dis 2018;77:1251–60.
[5]. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England) 2012;380:2163–96.
[6]. Van Manen MD, Nace J, Mont MA. Management of primary knee osteoarthritis and indications for total knee arthroplasty for general practitioners. J Am Osteopath Assoc 2012;112:709–15.
[7]. Williams QI, Gunn AH, Beaulieu JE, et al. Physical therapy vs. internet-based exercise training (PATH-IN) for patients with knee osteoarthritis: study protocol of a randomized controlled trial. BMC Musculoskelet Disord 2015;16:264.
[8]. Price AJ, Alvand A, Troelsen A, et al. Knee replacement. Lancet (London, England) 2018;392:1672–82.
[9]. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019;27:1578–89.
[10]. Lubis AMT, Wonggokusuma E, Marsetio AF. Intra-articular recombinant human growth hormone injection compared with hyaluronic acid and placebo for an osteoarthritis model of New Zealand rabbits. Knee Surg Relat Res 2019;31:44–53.
[11]. Strauss EJ, Hart JA, Miller MD, et al. Hyaluronic acid viscosupplementation and osteoarthritis: current uses and future directions. Am J Sports Med 2009;37:1636–44.
[12]. Lana JF, Weglein A, Sampson SE, et al. Randomized controlled trial comparing hyaluronic acid, platelet-rich plasma and the combination of both in the treatment of mild and moderate osteoarthritis of the knee. J Stem Cells Regen Med 2016;12:69–78.
[13]. Rachul C, Rasko JEJ, Caulfield T. Implicit hype? Representations of platelet rich plasma in the news media. PloS One 2017;12:e0182496.
[14]. Belk JW, Kraeutler MJ, Houck DA, et al. Platelet-Rich plasma versus hyaluronic acid for knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Am J Sports Med 2020. 363546520909397Online ahead of print.
[15]. Chen Z, Wang C, You D, et al. Platelet-rich plasma versus hyaluronic acid in the treatment of knee osteoarthritis: a meta-analysis. Medicine 2020;99:e19388.
[16]. Filardo G, Previtali D, Napoli F, et al. PRP injections for the treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials. Cartilage 2020;Online ahead of print.
[17]. Han Y, Huang H, Pan J, et al. Meta-analysis comparing platelet-rich plasma vs hyaluronic acid injection in patients with knee osteoarthritis. Pain Med (United States) 2019;20:1418–29.
[18]. Hohmann E, Tetsworth K, Glatt V. Is platelet-rich plasma effective for the treatment of knee osteoarthritis? A systematic review and meta-analysis of level 1 and 2 randomized controlled trials. Europ J Orthop Surg Traumatol 2020;30:955–67.
[19]. Luo P, Xiong Z, Sun W, et al. How to choose platelet-rich plasma or hyaluronic acid for the treatment of knee osteoarthritis in overweight or obese patients: a meta-analysis. Pain Res Management 2020;2020:7587936Online ahead of print.
[20]. Tan J, Chen H, Zhao L, et al. Platelet rich plasma versus hyaluronic acid in the treatment of knee osteoarthritis: a meta-analysis of 26 randomized controlled trials. Arthroscopy 2020;S0749-8063:30604–6. Online ahead of print.
[21]. Wu Q, Luo X, Xiong Y, et al. Platelet-rich plasma versus hyaluronic acid in knee osteoarthritis: a meta-analysis with the consistent ratio of injection. J Orthop Surg 2020;28:2309499019887660.
[22]. Zhao J, Huang H, Liang G, et al. Effects and safety of the combination of platelet-rich plasma (PRP) and hyaluronic acid (HA) in the treatment of knee osteoarthritis: a systematic review and meta-analysis. BMC Musculoskeletal Disorders 2020;21:224.
[23]. Gao DM. Comparison of Clinical Efficacy between Single and Double Injection of Leukocyte-Poor Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis. Shandong, China: Shandong University, Shandong University; 2019.
[24]. Görmeli G, Görmeli CA, Ataoglu B, et al. Multiple PRP injections are more effective than single injections and hyaluronic acid in knees with early osteoarthritis: a randomized, double-blind, placebo-controlled trial. Knee Surg Sports Traumatol Arthrosc 2017;25:958–65.
[25]. Kavadar G, Demircioglu DT, Celik MY, et al. Effectiveness of platelet-rich plasma in the treatment of moderate knee osteoarthritis: a randomized prospective study. J Phys Ther Sci 2015;27:3863–7.
[26]. Patel S, Dhillon MS, Aggarwal S, et al. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med 2013;41:356–64.
[27]. Simental-Mendía M, Acosta-Olivo CA, Hernández-Rodríguez AN, et al. Intraarticular injection of platelet-rich plasma in knee osteoarthritis: single versus triple application approach. Pilot study. Acta Reumatol Port 2019;44:138–44.
[28]. Tavassoli M, Janmohammadi N, Hosseini A, et al. Single- and double-dose of platelet-rich plasma versus hyaluronic acid for treatment of knee osteoarthritis: a randomized controlled trial. World J Orthop 2019;10:310–26.
[29]. Uslu Güvendi E, Aşkin A, Güvendi G, et al. Comparison of efficiency between corticosteroid and platelet rich plasma injection therapies in patients with knee osteoarthritis. Arch Rheumatol 2018;33:273–81.
[30]. Vilchez-Cavazos F, Millán-Alanís JM, Blázquez-Saldaña J, et al. Comparison of the clinical effectiveness of single versus multiple injections of platelet-rich plasma in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Orthop J Sports Med 2019;7:2325967119887116.
[31]. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011 Available from www.handbookcochraneorg.
[32]. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
[33]. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
[34]. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions version 5.0.0. Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie 2008;5:S38.
[35]. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.
[36]. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.
[37]. Page MJ, McKenzie JE, Higgins JPT. Tools for assessing risk of reporting biases in studies and syntheses of studies: a systematic review. BMJ Open 2018;8:e019703.
[38]. Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33:607–17.
[39]. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105–24.
[40]. Sutton A, Ades AE, Cooper N, et al. Use of Indirect and mixed treatment comparisons for technology assessment. PharmacoEconomics 2008;26:753–67.
[41]. Campbell KA, Saltzman BM, Mascarenhas R, et al. Does Intra-articular platelet-rich plasma injection provide clinically superior outcomes compared with other therapies in the treatment of knee osteoarthritis? A systematic review of overlapping meta-analyses. Arthroscopy 2015;31:2213–21.
[42]. Khoshbin A, Leroux T, Wasserstein D, et al. The efficacy of platelet-rich plasma in the treatment of symptomatic knee osteoarthritis: a systematic review with quantitative synthesis. Arthroscopy 2013;29:2037–48.
[43]. Meheux CJ, McCulloch PC, Lintner DM, et al. Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. Arthroscopy 2016;32:495–505.
[44]. Schmal H, Marintschev I, Salzmann GM. Current status of anti-inflammatory therapy for posttraumatic osteoarthritis. Acta Orthop Belg 2016;82:427–39.
[45]. Ricci M, Micheloni GM, Berti M, et al. Clinical comparison of oral administration and viscosupplementation of hyaluronic acid (HA) in early knee osteoarthritis. Musculoskelet Surg 2017;101:45–9.
[46]. Day R, Brooks P, Conaghan PG, et al. A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee. J Rheumatol 2004;31:775–82.
[47]. Petrella RJ, Petrella M. A prospective, randomized, double-blind, placebo controlled study to evaluate the efficacy of intraarticular hyaluronic acid for osteoarthritis of the knee. J Rheumatol 2006;33:951–6.
[48]. Jüni P, Reichenbach S, Dieppe P. Osteoarthritis: rational approach to treating the individual. Best Pract Res Clin Rheumatol 2006;20:721–40.
[49]. Chevalier X, Jerosch J, Goupille P, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheumat Dis 2010;69:113–9.
[50]. Laudy AB, Bakker EW, Rekers M, et al. Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis. Br J Sports Med 2015;49:657–72.
[51]. Chang KV, Hung CY, Aliwarga F, et al. Comparative effectiveness of platelet-rich plasma injections for treating knee joint cartilage degenerative pathology: a systematic review and meta-analysis. Arch Phys Med Rehabil 2014;95:562–75.
[52]. Kenmochi M. Clinical outcomes following injections of leukocyte-rich platelet-rich plasma in osteoarthritis patients. J Orthop 2020;18:143–9.
Keywords:

intra-articular injection; knee osteoarthritis; network meta-analysis; platelet-rich plasma; protocol

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.